Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Swedbank AB

Swedbank AB boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 245.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 77,400 shares of the company's stock after acquiring an additional 55,000 shares during the period. Swedbank AB owned 0.25% of Medpace worth $25,715,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. R Squared Ltd acquired a new position in shares of Medpace in the 4th quarter valued at $30,000. Stone House Investment Management LLC purchased a new stake in Medpace in the 3rd quarter valued at about $33,000. Ashton Thomas Securities LLC acquired a new position in Medpace in the third quarter valued at about $37,000. Capital Performance Advisors LLP purchased a new position in Medpace during the third quarter worth about $46,000. Finally, True Wealth Design LLC increased its position in shares of Medpace by 16,800.0% during the third quarter. True Wealth Design LLC now owns 169 shares of the company's stock valued at $56,000 after acquiring an additional 168 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Performance

Shares of MEDP traded down $6.42 during midday trading on Monday, hitting $342.73. The company had a trading volume of 147,737 shares, compared to its average volume of 208,663. Medpace Holdings, Inc. has a 1 year low of $291.15 and a 1 year high of $459.77. The firm has a market capitalization of $10.65 billion, a P/E ratio of 30.12, a P/E/G ratio of 1.79 and a beta of 1.36. The company's 50-day simple moving average is $342.50 and its 200-day simple moving average is $351.36.

Wall Street Analysts Forecast Growth

MEDP has been the topic of several recent analyst reports. Robert W. Baird upped their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. William Blair restated an "outperform" rating on shares of Medpace in a research note on Tuesday, October 22nd. Baird R W cut Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. TD Cowen cut their price objective on Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a report on Wednesday, October 23rd. Finally, Redburn Atlantic assumed coverage on Medpace in a report on Monday, October 14th. They set a "buy" rating and a $404.00 target price for the company. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.